Enrolling
Association of vitamin D insufficiency with non-alcoholic fatty liver disease in HIV mono-infected patients
Learn MoreStart-up
Falls in older persons with HIV: Frequency, risk factors and feasibility of a future interventional trial
Learn MoreCompleted
Exploring the role of the soluble glycoprotein 120 as a pan-toxin driving immune dysfunction and accelerated aging in people living with HIV
Learn MoreOngoing
A learning health system to improve care in people living with HIV
Learn MoreEnrolling
Ongoing
Interplay between expanded endocannabinoid (eCB) system and inflamm-aging: Implication for accelerated atherosclerosis in people living with HIV (PLWH) under ART
Learn MoreEnrolling
The role of female sex hormones and chronic/latent co-infections on cellular aging and comorbidities in women living with HIV
Learn MoreReporting
Understanding COVID-19 vaccine confidence in people living with HIV in Canada: A pan-Canadian survey
Learn MoreOngoing
Influence of a 3-month letermovir treatment on gut inflammation in ART-treated HIV-infected persons in an open labelled controlled randomized study
Learn More
CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.
